期刊文献+

正常CA125水平的卵巢癌患者血清和尿液中MMP-2水平变化 被引量:1

Levels of serum and urine MMP-2 in patients with normal CA125 level for diagnosis of ovarian cancer
下载PDF
导出
摘要 目的:探讨在正常和异常CA125水平的卵巢癌患者血清和尿液MMP-2水平的变化。方法:选取83例卵巢癌患者(CA125正常的卵巢癌患者38例,CA125异常的卵巢癌患者45例),50例健康体检妇女为研究对象。用ELISA方法测定血清和尿液中MMP-2的水平。结果:CA125正常和异常的卵巢癌组血清和尿液中MMP-2水平明显高于对照组(P<0.01)。血清MMP-2和尿液MMP-2诊断卵巢癌的ROC曲线下面积分别为0.846和0.860(P<0.01);血清MMP-2和尿液MMP-2在CA125正常情况下诊断卵巢癌的ROC曲线下面积分别为0.814和0.853(P<0.01)。尿液MMP-2和CA125的联合诊断达到最高灵敏度96.7%和特异度92.5%。结论:血清与尿液中MMP-2的检测可以用于卵巢癌的辅助诊断。 Objective:To evaluate serum and urine matrix metalloproteinase-2(MMP-2) in patients with normal or abnormal CA125 level for diagnosis of ovarian cancer.Methods:A total of 83 patients with ovarian cancer(38 patients with normal CA125 level,45 patients with abnormal CA125 level),and 50 healthy controls were recruited in this study.Serum and urine levels of MMP-2 were measured by ELISA methods.Results:Serum and urine levels of MMP-2 in ovarian cancer patients with normal or abnormal CA125 level were higher significantly than those in healthy controls(P0.01).Receiver operating characteristic(ROC) curves of serum and urine MMP-2 for diagnosis of ovarian cancer were 0.846 and 0.860,respectively.ROC curves of serum and urine MMP-2 in patients with normal CA125 level for diagnosis of ovarian cancer were 0.814 and 0.853,respectively.The combined detection of urine MMP-2 and CA125 reached the highest sensitivity of 96.7% and specificity of 92.5%.Conclusion:Serum and urine MMP-2 may represent the helpful adjunct to conventional diagnostic tools in ovarian cancer.
作者 程大也 孔虹
出处 《现代肿瘤医学》 CAS 2012年第10期2148-2150,共3页 Journal of Modern Oncology
基金 辽宁省科技厅自然科学基金项目资助(编号:201102257)
关键词 卵巢癌 基质金属蛋白酶-2 血清 尿液 ovarian cancer matrix metalloproteinase-2 serum urine
  • 相关文献

参考文献6

  • 1Bhoola S, Hoskins WJ. Diagnosis and management of epithelial o- varian cancer [ J]. Obstet Gyneco1,2006,107 ( 6 ) : 1399 - 1410.
  • 2Coticchia CM, Curatolo AS, Zurakowski D, et al. Urinary MMP - 2 and MMP - 9 predict the presence of ovarian cancer in women with normal CA125 levels [ J ]. Gynecol Oncol, 2011,123 ( 2 ) : 295 - 300.
  • 3Sato H. Tumor metastasis and MMP inhibitor [ J ]. Clin Calcium, 2006,16(4) : 621 - 626.
  • 4Schmalfeldt B, Prechtel D, Hatrting K, et al. Increased expression of matrix metalloproteinases (MMP) - 2, MMP - 9, and the urokinase - type plasminogen activator is associated with progression from be- nign to advanced ovarian cancer [ J ]. Clin Cancer Res, 2001,7 ( 8 ) : 2396 - 2404.
  • 5Kenny HA, Lengyel E. MMP - 2 functions as an early response pro- tein in ovarian cancer metastasis [ J ]. Cell Cycle ,2009,8 (5) : 683 - 688.
  • 6Klug TL, Bast RC Jr, Niloff JM, et al. Monoclonal antibody immuno- radiometric assay for an antigenic determinant ( CA125 ) associated with human epithelial ovarian carcinomas [ J ]. Cancer Res, 1984, 44(3) :1048 - 1053.

同被引文献8

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部